Trial Profile
Phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil; Mitomycin
- Indications Adenocarcinoma; Bladder cancer; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TUXEDO
- 31 Jul 2022 Results published in the BJU International
- 06 Jun 2017 Combined results of phases I/II, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 09 Mar 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.